e-Letters – Observations

e157 Preventive Care in Type 2 Diabetes: Results of a Randomized, Controlled Trial in Community Pharmacies
K. Prax, K. Schmiedel, T. Hepp, H. Schlager, and K. Friedland

e160 Diabetes Technology Use for Management of Type 1 Diabetes Is Associated With Fewer Adverse COVID-19 Outcomes: Findings From the T1D Exchange COVID-19 Surveillance Registry
N. Noor, O. Ebekeozien, L. Levin, S. Stone, D.P. Sparling, R. Rapaport, and D.M. Maahs

e163 Impact of COVID-19 on Diabetes Health Care and Service Provision in Australian Diabetes Centers
M. Quigley, A. Earnest, N. Szwarcbard, N. Wischer, and S. Zoungas

e-Letters – Comments and Responses

e165 Comment on Albogami et al. Glucagon-Like Peptide 1 Receptor Agonists and Chronic Lower Respiratory Disease Exacerbations Among Patients With Type 2 Diabetes. Diabetes Care 2021;44:1344–1352
D. Foer and K.N. Cahill

e167 Response to Comment on Albogami et al. Glucagon-Like Peptide-1 Receptor Agonists and Chronic Lower Respiratory Disease Exacerbations Among Patients With Type 2 Diabetes. Diabetes Care 2021;44:1344–1352
Y. Albogami, K. Cusi, M.J. Daniels, Y.-J.J. Wei, and A.G. Winterstein